Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9258846 | 0.81 | SMN1; SMN2 (0.35) | POLBGAASMN1; SMN2F10 | |
| SCHEMBL31126065 | 0.69 | POLB (0.40) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL16908831 | 0.67 | POLB (0.38) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL21169723 | 0.65 | KDM1A (0.41) | SMN1; SMN2 | |
| SCHEMBL16429126 | 0.64 | PTGS2 (0.44) | GAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL20551743 | 0.62 | PRMT5 (0.37) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL17683228 | 0.62 | KMT2A (0.37) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL8644630 | 0.62 | PRMT5 (0.40) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL27353148 | 0.61 | — | — | |
| SCHEMBL4600005 | 0.60 | PRMT5 (0.36) | POLBGAASMN1; SMN2PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511327-B1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | LANOVA MEDICINES LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10882853-B2 | Tyrosine kinase inhibitor and application thereof | LaNova Medicines Limited (CN) | 2021-01-05 | — | — | US | disclosed |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | SHANGHAI XIANGJIN BIOTECHNOLOGY CO., LTD. (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3511327-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | Shanghai Xiangjin Biotechnology Co., Ltd (CN) | 2019-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882853-B2 | Tyrosine kinase inhibitor and application thereof | KDR, FLT1, FLT4 | POLB 3922/4885GAA 3795/4885SMN1; SMN2 4594/4885 |
| US-20190248772-A1 | TYROSINE KINASE INHIBITOR AND APPLICATION THEREOF | KDR, FLT1, MET | POLB 3576/4885GAA 3073/4885SMN1; SMN2 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.